Allogene Therapeutics, Inc. (NASDAQ:ALLO) Financings

Allogene Therapeutics, Inc.

Financings

RaiseDate
Public offering of common stock
Update: US$175M · US$2 a share · Goldman Sachs & Co. LLC +7
Dealers: Goldman Sachs & Co. LLC (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Piper Sandler (co-lead), William Blair (co-lead), TPG Capital BD, LLC, Baird, Canaccord Genuity
Use of proceeds: General corporate purposes, which may include clinical trial, R&D, G&A expenses and capital expenditures
Apr 14, 2026

Read by 6ix AI from the company's releases